NEW YORK, Nov. 3, 2015 /PRNewswire/ -- Medivo, Inc., a
leader in lab data analytics, today announced that it has formed a
nonexclusive laboratory data licensing agreement with Quest
Diagnostics (NYSE: DGX), the world's leading provider of diagnostic
information services. The agreement is designed to enhance Medivo's
ability to identify opportunities to educate physicians about new
and potentially under-utilized drug therapies that could improve
outcomes for patients.
"Our agreement with Medivo is the latest in a series of steps
Quest has taken this year to further leverage our lab data to drive
better outcomes," said David
Freeman, general manager, Quest Diagnostics Information
Ventures. "Through collaborations with progressive healthcare
solutions companies like Medivo, and our own clinical and
technology expertise, we are committed to providing insights that
are actionable, not just for physicians and patients, but for
therapy developers, health plans and health systems. We look
forward to collaborating with Medivo to realize the full value of
this unique competency to drive better healthcare."
Under the agreement, Quest Diagnostics will provide clinical and
bioinformatics expertise as well as analysis of its de-identified
laboratory data to Medivo, in order to identify patterns in test
ordering and result values in specific clinical disease categories.
Medivo uses these results, in conjunction with other datasets, to
identify physicians whose patients may benefit from FDA approved
drugs. One example is the new class of cholesterol lowering drugs,
PCSK9 inhibitors, which may be effective in patients in whom
traditional statins are ineffective.
In addition, Quest's scale in highly advanced genomic and
genetic tests for low-prevalence diseases makes Quest's data
potentially helpful in linking "orphan" drugs with the caregivers
of patients with low-prevalent and rare disorders.
"Medivo's analytic solutions are designed to transform lab data
into actionable information. While we currently service the
majority of the top 15 pharma companies, analyses based on the
addition of Quest's 20 billion laboratory test results allows us to
provide solutions for more conditions to more brands. Through
this relationship, Quest and Medivo will enhance the ability of
laboratory data to inform physicians, and improve the odds patients
can access the treatments that will help them." said Sundeep Bhan, CEO of Medivo.
"With more than 40 drug therapies approved by the FDA last year
alone, it is virtually impossible for physicians to stay on top of
the various options available to them to help improve treatment for
their patients," said Harvey W.
Kaufman, MD, senior medical director, Quest Diagnostics.
"Because of Quest's analytics expertise and massive datasets, the
addition of Quest's data to Medivo's analytics solutions will
greatly improve the ability to focus outreach programs to help
patients gain access to therapies that will potentially benefit
them."
The Quest Diagnostics database consists of more than 20 billion
laboratory test results on conditions ranging from diabetes,
cholesterol, oncology, pregnancy health and other clinical areas.
The company participates in data analytics research of this data in
de-identified form with top public and private healthcare
institutions, including the Centers for Disease Control and
Prevention (CDC) and UCSF, to enhance public and private health
initiatives. Quest also routinely publishes novel research of
insights on this de-identified data in peer-reviewed publications
as part of its Quest Diagnostics Health Trends™ series of
reports. In October, Quest and Inovalon launched Data
Diagnostics™, a suite of hundreds of real-time patient-specific
data analyses that clinicians can order individually, on demand at
the point of care, to identify and address gaps in quality, risk,
utilization and medical history insights. Quest also
collaborates with partners on select pre-clinical drug development
data analysis.
About Medivo
Medivo is a healthcare data analytics
company that unlocks the power of lab data to improve health.
Medivo is the largest source of lab data in the U.S., with access
to over 150M patients through its nationwide network of partner
labs. Labs are able to de-identify data on their premises using
Medivo's OPAL™ De-Identification Software. Medivo then analyzes
these large, de-identified data sets and shares its findings with
the medical community at large, as well as with its life science,
payer and lab partners, to ensure that appropriate available
treatments are provided to patients sooner. Founded in 2010,
Medivo's investors include Safeguard Scientifics, Inc. (NYSE:SFE)
and Merck Global Health Innovation Fund (GHIF). For more
information, visit www.medivo.com.
Logo -
http://photos.prnewswire.com/prnh/20151102/282959LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/medivo-forms-agreement-with-quest-diagnostics-to-analyze-laboratory-data-to-help-pharmaceutical-companies-match-caregivers-with-therapies-300171031.html
SOURCE Medivo